Please assess the completion status of the following clinical trial:

Trial Title: Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.~* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.~* Written or oral, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.~* Free of any known or suspected health problems (as established by medical history and clinical examination before entering into the study).~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.~* A family history of congenital or hereditary immunodeficiency.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (with the exception of hepatitis B immunoglobulins at birth).~* Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception of hepatitis B vaccination at birth or at least 30 days before the subject's first study visit).~* History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B, Streptococcus and Haemophilus influenzae type b disease.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* History of any neurological disorders or seizures.~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Babies for which birth weight is \< 2 kilogram.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Study Arms:
- Synflorix & Tritanrix-HebB/Hib Group (Type: EXPERIMENTAL): Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
- Hiberix group & Tritanrix-HebB Group (Type: ACTIVE_COMPARATOR): Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete